Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacologys

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 3, 2013, Pages 599-606

  Caron, Whitney P ^a   Lay, John C ^b   Fong, Alan M ^b   La Beck, Ninh M ^b,e   Kumar, Parag ^a   Newman, Suzanne E ^a   Zhou, Haibo ^c   Monaco, Jane H ^c   Clarke Pearson, Daniel L ^d   Brewster, Wendy R ^b,d   Van Le, Linda ^b,d   Bae Jump, Victoria L ^b,d   Gehrig, Paola A ^b,d   Zamboni, William C ^a,d,f  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f North Carolina Biomedical Innovation Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELOTECAN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; LIPOSOME; MACROGOL; NANOPARTICLE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOG; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; OVARY CARCINOMA; PATIENT; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; SOLID TUMOR; SPECIES DIFFERENCE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DENDRITIC CELLS; DOGS; DRUG COMPOUNDING; FEMALE; HALF-LIFE; HUMANS; LIPOSOMES; MICE; MIDDLE AGED; MONONUCLEAR PHAGOCYTE SYSTEM; NANOPARTICLES; OVARIAN NEOPLASMS; PHAGOCYTOSIS; PHARMACOKINETICS; PHENOTYPE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887867927     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208801     Document Type: Article

References (35)

1. Amantea MA, Forrest A, Northfelt D.W., and Mamelok R (1997) Population phar-macokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 61:301-311. (Pubitemid 27145431)
2. Bookman MA (2005) Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 15 (Suppl 3):212-220. (Pubitemid 43096584)
3. Calvert AH, Newell DR, Gumbrell L.A., O'Reilly S, Burnell M, Boxall F.E., Siddik ZH, Judson IR, Gore ME, and Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756. (Pubitemid 19272848)
4. Caron WP, Clewell H, Dedrick R., Ramanathan RK, Davis WL, Yu N, Tonda M., Schellens JH, Beijnen JH, and Zamboni WC (2011) Allometric scaling of pegylated liposomal anticancer drugs. J Pharmacokinet Pharmacodyn 38:653-669.
5. Caron WP, Song G, Kumar P., Rawal S, and Zamboni WC (2012) Interpatient phar-macokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. Clin Pharmacol Ther 91:802-812.
6. Dobrovolskaia MA, Aggarwal P, Hall J.B., and McNeil SE (2008) Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 5:487-495.
7. Egorin MJ, Reyno LM, Canetta R.M., Jodrell DI, Swenerton KD, Pater JL, Burroughs J.N., Novak MJ, and Sridhara R (1994) Modeling toxicity and response in carboplatin-based combination chemotherapy. Semin Oncol 21(5, Suppl 12)7-19. (Pubitemid 24378882)
8. Elbim C and Lizard G (2009) Flow cytometric investigation of neutrophil oxidative burst and apoptosis in physiological and pathological situations. Cytometry A 75: 475-481.
9. Fumarulo R, Giordano D, Riccardi S., and Aresta M (1980) Modification of macro-phages chemotaxis caused by cis-Pt(NH3)2Cl2. Proc Soc Exp Biol Med 164: 164-166. (Pubitemid 11254991)
10. Gabizon A, Catane R, Uziely B., Kaufman B, Safra T, Cohen R., Martin F, Huang A, and Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992. (Pubitemid 24085451)
11. Gabizon A, Shmeeda H, and Barenholz Y (2003) Pharmacokinetics of pegylated li-posomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436. (Pubitemid 36649037)
12. Gabizon A, Isacson R, Rosengarten O., Tzemach D, Shmeeda H, and Sapir R (2008) An open-label study to evaluate dose and cycle dependence of the pharmacoki-netics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 61: 695-702.
13. Hume DA, Ross IL, Himes S.R., Sasmono RT, Wells CA, and Ravasi T (2002) The mononuclear phagocyte system revisited. J Leukoc Biol 72:621-627. (Pubitemid 36277831)
14. La-Beck N.M., Zamboni BA, Gabizon A, Schmeeda H., Amantea M, Gehrig PA, and Zamboni WC (2011) Factors affecting the pharmacokinetics of pegylated li-posomal doxorubicin in patients. Cancer Chemother Pharmacol 69:43-50.
15. Lee JH, Lee JM, Lim K.H., Kim JK, Ahn SK, Bang YJ, and Hong CI (2000) Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci 922:324-325. (Pubitemid 32050270)
16. Lichanska AM, Browne CM, Henkel G.W., Murphy KM, Ostrowski MC, McKercher SR, Maki R.A., and Hume DA (1999) Differentiation of the mononuclear phagocyte system during mouse embryogenesis: the role of transcription factor PU.1. Blood 94:127-138. (Pubitemid 29300141)
17. Meerum Terwogt J.M., Groenewegen G, Pluim D., Maliepaard M, Tibben MM, Huis-man A, ten Bokkel Huinink WW, Schot M, Welbank H, and Voest EE, et al. (2002) Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 49:201-210. (Pubitemid 34185593)
18. Meerum Terwogt J.M., Tibben MM, Welbank H, Schellens J.H., and Beijnen JH (2000) Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spec-trometry. Fresenius J Anal Chem 366:298-302.
19. Nielsen H (1984) Effect of cis-platinum on human blood monocyte function in vitro. Cancer Immunol Immunother 18:223-225. (Pubitemid 15179776)
20. Nielsen H, Rørth M, and Bennedsen J (1985) Monocyte chemotaxis in patients with nonseminomatous testicular carcinoma. Effect of chemotherapy. Cancer Immunol Immunother 19:68-71. (Pubitemid 15110999)
21. Ozols RF, Schwartz PE, and Eifel PJ (1997) Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma, in Cancer: Principles and practice of oncology (DeVita VT, Hellman S, and Rosenberg SA, eds) pp 1502-1534, Lippincott-Raven, Philadelphia.
22. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E., Matthay K, Huang SK, Lee K.D., Woodle MC, Lasic DD, and Redemann C, et al (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464. (Pubitemid 21916061)
23. Park JW, Benz CC, and Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31(6, Suppl 13)196-205. (Pubitemid 40023249)
24. Sidone B, Edwards R, Zamboni B., Strychor S, Maruca L, Zamboni W. (2007) Evalution of body surface area (BSA) based dosing, age, and body composition as factors affecting the pharmacokinetic (PK) variability of STEALTH liposomal doxorubicin (Doxil). AACR annual meeting abstracts C107.
25. Stewart CF, Arbuck SG, Fleming R.A., and Evans WE (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 8: 1874-1879. (Pubitemid 20382351)
26. Uziely B, Jeffers S, Isacson R., Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E., Muggia FM, and Gabizon A (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785.
27. van der Bol JM, Mathijssen RH, Creemers G.J., Planting AS, Loos WJ, Wiemer EA, Friberg L.E., Verweij J., Sparreboom A, and de Jong FA (2010) A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 16:736-742.
28. Wu H, Ramanathan RK, Zamboni B.A., Strychor S., Ramalingam S, Edwards RP, Friedland D.M., Stoller RG, Belani CP, Maruca LJ, et al (2011) Population phar-macokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. J Clin Pharmacol 52:180-194.
29. Zamboni WC and Tonda ME (2000) New designs of clinical trials. Highlights in Oncol Practice 18:2-7.
30. Zamboni WC (2008) Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 13:248-260. (Pubitemid 351679900)
31. Zamboni WC (2005) Liposomal, nanoparticle, and conjugated formulations of anti-cancer agents. Clin Cancer Res 11:8230-8234. (Pubitemid 41746931)
32. Zamboni WC, Eiseman JL, Strychor S, Rice P.M., Joseph E., Zamboni BA, Donnelly MK, Shurer J, Parise R.A., and Tonda ME, et al (2011a) Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. J Liposome Res 21:70-80.
33. Zamboni WC, Maruca LJ, Strychor S, Zamboni B.A., Ramalingam S., Edwards RP, Kim J, Bang Y, Lee H., and Friedland DM, et al (2011b) Bidirectional pharmaco-dynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res 21:158-165.
34. Zamboni WC, Ramalingam S, Friedland D.M., Edwards RP, Stoller RG, Strychor S, Maruca L., Zamboni BA, Belani CP, and Ramanathan RK (2009) Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 15:1466-1472.
35. Zamboni WC, Strychor S, Joseph E., Walsh DR, Zamboni BA, Parise RA, Tonda M.E., Yu NY, Engbers C, and Eiseman JL (2007) Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res 13:7217-7223. (Pubitemid 350276909)